Biogen Idec (NASDAQ:BIIB)

Comfortable hospital bed

Will Biogen Win From Novartis MS Drug Safety Label Change?

There are times when a negative piece of news in the BioPharma sector can actually help rival companies. Biogen Inc. (NASDAQ: BIIB) is a stock that has been battered of ...
Read Full Story »
Biotechnology word cloud

3 Potential Huge Takeover Targets in Biotech

Usually when you think of a biotech takeover, it is a large cap biotech or pharmaceutical company that dives in and buys a small market cap stock with solid clinical ...
Read Full Story »
78773961

Tech and Biotech See Big-Time Insider Buying This Week – Apple, Biogen, Qualcomm and More

Nothing like earnings season coming around to buy stock if you are an insider and your company happens to disappoint. While most of the S&P 500 companies have reported as ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AT&T, Chesapeake, Facebook, Qualcomm, Weatherford and Many More

Stocks were indicated lower by almost 1% on Monday after China's Shanghai market suffered its biggest loss in about 8 years on Monday. The one trend that has held up ...
Read Full Story »
biotech

Short Sellers Back Off Major Biotechs

The short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Pharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. ...
Read Full Story »
biotech

Why Biogen Shares Are Tumbling After Earnings Report

Biogen Inc. (NASDAQ: BIIB) reported second-quarter 2015 results before markets opened Friday. The biotech firm posted adjusted diluted earnings per share (EPS) of $4.22 on revenues of $2.59 billion. In ...
Read Full Story »
Money, US, $100 bills

What to Look for in Biogen Earnings Report

Biogen Inc. (NASDAQ: BIIB) is scheduled to release its second-quarter financial results before the markets open on Friday. Thomson Reuters has consensus estimates of $4.10 in earnings per share (EPS) ...
Read Full Story »
152498601

Biogen Faces Mixed Alzheimer’s Reception

Biogen Inc. (NASDAQ: BIIB) may have dropped Idec from its name recently, but now the company appears to be dropping some of the bullish hopes for its Alzheimer's drug candidate. ...
Read Full Story »
biotech

Top Health Care Earnings for the Week Ahead

Earnings season is hitting its stride next week, and we have taken a look at companies in a variety of sectors that will be posting results next week. The health ...
Read Full Story »
upgrade

Why Biogen Is Now a Buy on Weakness

Biogen Inc. (NASDAQ: BIIB), like other companies in the health care sector, has performed very well in 2015. However, within the past few months shares retreated from a 52-week high ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Amazon, Biogen, GoPro, Intel, Micron, SunPower and More

Stocks were indicated flat on Tuesday despite better news in Greece and an Iran deal. So far, in a trend that is nearing four years old, investors just keep buying ...
Read Full Story »
Biotechnology word cloud

Short Sellers Back Off Big Biotech

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
research

Biogen Loses Its Head of Research and Development

Biogen Inc. (NASDAQ: BIIB) may have recently (and finally) dropped the Idec from its name, but the company announced another big change on Friday. The biotech giant known for its ...
Read Full Story »
DNA

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »